An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023
1 Genetics, Vaccines and Paediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain.
2 Translational Paediatrics and Infectious Diseases, Hospital Clínico Universitario and University of Santiago de Compostela (USC), Santiago de Compostela, Spain.
3 World Health Organization Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain.
4 Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
5 Dirección Xeral de Saude Pública, Consellería de Sanidade, Xunta de Galicia, Galicia, Spain.
Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023
Federico Martinón-Torres et al.
Euro Surveill.2023 Dec.
1 Genetics, Vaccines and Paediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain.
2 Translational Paediatrics and Infectious Diseases, Hospital Clínico Universitario and University of Santiago de Compostela (USC), Santiago de Compostela, Spain.
3 World Health Organization Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain.
4 Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
5 Dirección Xeral de Saude Pública, Consellería de Sanidade, Xunta de Galicia, Galicia, Spain.
A monoclonal antibody for universal respiratory syncytial virus prophylaxis in infants has recently been licensed. We share our experiences of integrating nirsevimab into the regional immunisation programme in Galicia, Spain. After a 3-week hospital-based immunisation campaign with flexible individualised appointments and educational activities, nirsevimab uptake was 97.5% in the high-risk group, 81.4% in the catch-up group and 92.6% in infants born during the campaign. This successful implementation strategy can serve as a model and may inform other countries' programmatic deliberations.
Conflict of interest: Federico Martinón-Torres has acted as principal investigator in randomised controlled trials of Ablynx, Abbot, Seqirus, Sanofi Pasteur MSD, Sanofi Pasteur, Cubist, Wyeth, Merck, Pfizer, Roche, Regeneron, Jansen, Medimmune, Novavax, Novartis and GSK, with honoraria paid to his institution. Federico Martinon-Torres reports a relationship with GSK Vaccines SRL that includes: consulting or advisory. Federico Martinon-Torres reports a relationship with Pfizer Inc that includes: consulting or advisory. Federico Martinon-Torres reports a relationship with Sanofi Pasteur Inc that includes: consulting or advisory. Federico Martinon-Torres reports a relationship with Janssen Pharmaceuticals Inc that includes: consulting or advisory. Federico Martinon-Torres reports a relationship with MSD that includes: consulting or advisory. Federico Martinon-Torres reports a relationship with Seqirus Pty Ltd that includes: consulting or advisory. The remaining authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
Wildenbeest JG, Billard MN, Zuurbier RP, Korsten K, Langedijk AC, van de Ven PM, et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med. 2023;11(4):341-53. 10.1016/S2213-2600(22)00414-3
-
DOI
-
PMC
-
PubMed
Langedijk AC, Bont LJ. Respiratory syncytial virus infection and novel interventions. Nat Rev Microbiol. 2023;21(11):734-49. 10.1038/s41579-023-00919-w
-
DOI
-
PubMed
Martinón-Torres F, Navarro-Alonso JA, Garcés-Sánchez M, Soriano-Arandes A. The path towards effective respiratory syncytial virus immunization policies: recommended actions. Arch Bronconeumol. 2023;59(9):581-8. 10.1016/j.arbres.2023.06.006
-
DOI
-
PubMed
Martinón-Torres F, Carmo M, Platero L, Drago G, López-Belmonte JL, Bangert M, et al. Clinical and economic hospital burden of acute respiratory infection (BARI) due to respiratory syncytial virus in Spanish children, 2015-2018. BMC Infect Dis. 2023;23(1):385. 10.1186/s12879-023-08358-x
-
DOI
-
PMC
-
PubMed
Martinón-Torres F, Carmo M, Platero L, Drago G, López-Belmonte JL, Bangert M, et al. Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study. BMC Infect Dis. 2022;22(1):759. 10.1186/s12879-022-07745-0
-
DOI
-
PMC
-
PubMed